Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer [0.03%]
应用巴贝斯虫和旋毛虫抗原的免疫疗法治疗结肠癌小鼠模型的研究
Maha M Eissa,Cherine A Ismail,Mervat Z El-Azzouni et al.
Maha M Eissa et al.
Considerable evidence indicates a negative correlation between the prevalence of some parasitic infections and cancer and their interference with tumor growth. Therefore, parasitic antigens seem to be promising candidates for cancer immunot...
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer [0.03%]
一项评估MEK抑制剂Binimetinib治疗晚期或转移性胆道癌患者的2期临床研究
R S Finn,D H Ahn,M M Javle et al.
R S Finn et al.
Background The MAPK pathway plays a central role in regulation of several cellular processes, and its dysregulation is a hallmark of biliary tract cancer (BTC). Binimetinib (MEK162), a potent, selective oral MEK1/2 inhibitor, was assessed i...
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors [0.03%]
针对晚期实体瘤患者，一项1b期关于成纤维细胞生长因子受体抑制剂NEDD8活化酶抑制剂pevonedistat联合多西他赛+卡铂、紫杉醇或吉西他滨的研究
A Craig Lockhart,Todd M Bauer,Charu Aggarwal et al.
A Craig Lockhart et al.
Purpose This phase Ib study (NCT01862328) evaluated the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors. Methods Patients received pevonedi...
Clinical Trial
Investigational new drugs. 2019 Feb;37(1):87-97. DOI:10.1007/s10637-018-0610-0 2019
Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology - phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells [0.03%]
用于实验肿瘤学的简单茋类化合物及苯并氧基硼唑衍生物——A2780卵巢癌细胞周期特异性凋亡诱导剂
Mateusz Psurski,Agnieszka Łupicka-Słowik,Agnieszka Adamczyk-Woźniak et al.
Mateusz Psurski et al.
Objective The aim of the study was to evaluate the antiproliferative potential of simple phenylboronic acid and benzoxaborole derivatives as well as to provide preliminary insight into their mode of action in cancer cells in vitro. Methods ...
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers [0.03%]
一项Ⅰ期临床试验评估艾沙拉克002（一种口服MET谱系激酶抑制剂）在晚期或转移性实体瘤患者中的安全性和药代动力学的疗效
Aflah Roohullah,Adam Cooper,Anna J Lomax et al.
Aflah Roohullah et al.
Background The MET tyrosine kinase and its ligand, hepatocyte growth factor (HGF) also known as scatter factor, are associated with tumourigenesis and metastasis by promotion of scattering, proliferation, angiogenesis, motility and invasion...
Clinical Trial
Investigational new drugs. 2018 Oct;36(5):886-894. DOI:10.1007/s10637-018-0588-7 2018
Myrna Hurtado,Umesh T Sankpal,Jaya Chhabra et al.
Myrna Hurtado et al.
The non-steroidal anti-inflammatory drug, Tolfenamic acid (TA) acts as an anti-cancer agent in several adult and pediatric cancer models. Copper (Cu) is an important element with multiple biological functions and has gained interest in medi...
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose [0.03%]
一种针对HER2/HER3双特异性单克隆抗体MCLA-128的转化PK-PD模型分析，预测有效药物浓度和剂量临床试验中的有效性
Aurelia H M de Vries Schultink,Robert P Doornbos,Alexander B H Bakker et al.
Aurelia H M de Vries Schultink et al.
Introduction MCLA-128 is a bispecific monoclonal antibody targeting the HER2 and HER3 receptors. Pharmacokinetics (PK) and pharmacodynamics (PD) of MCLA-128 have been evaluated in preclinical studies in cynomolgus monkeys and mice. The aim ...
A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma [0.03%]
伊立替康，卡培他滨和奥沙利铂（IXO）一线治疗转移性胃或胃食管交界处腺癌的多中心开放标签II期临床研究
Arthur Lui,Karen Mulder,Christine Brezden-Masley et al.
Arthur Lui et al.
Purpose Chemotherapy remains the primary treatment for metastatic gastric/GEJ cancer but optimal agents and schedule remain controversial. This study examined the safety and efficacy of first-line Irinotecan, capecitabine (Xeloda®), and Ox...
Clinical Trial
Investigational new drugs. 2018 Aug;36(4):674-682. DOI:10.1007/s10637-018-0599-4 2018
Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report [0.03%]
奥希替尼诱导的发热和肝毒副作用后的口服脱敏治疗案例报告：奥希替尼脱敏治疗成功案例报告
Ryosuke Hirabayashi,Daichi Fujimoto,Yukari Satsuma et al.
Ryosuke Hirabayashi et al.
Osimertinib is a standard second-line therapy for patients who develop EGFR Thr790Met resistance mutation after treatment with first-line epidermal growth factor receptor tyrosine kinase inhibitors. Although no other effective targeted trea...
Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists [0.03%]
人急性髓系白血病细胞表达神经激肽-1受体并参与其受体拮抗剂的抗白血病效应
A Molinos-Quintana,P Trujillo-Hacha,J I Piruat et al.
A Molinos-Quintana et al.
The substance P/neurokinin-1 receptor system has been implicated in tumor cell proliferation. Neurokinin-1 receptor has been identified in different solid tumors but not frequently in hematopoietic malignant cells. We investigated the prese...